Black Diamond Therapeutics, Inc. (BDTX) trades at a trailing P/E of 6.3. Trailing earnings yield is 15.80%. Graham Number is $4.16.
Criteria proven by this page:
Overall SharesGrow Score: 81/100 with 5/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2017 | -61.7 | 0.00 | -42.56 | 0.00 | - |
| 2018 | -61.7 | 0.00 | -35.44 | 0.00 | - |
| 2019 | -40.2 | -0.50 | -30.06 | 0.00 | - |
| 2020 | -15.7 | -0.20 | 3.43 | 0.00 | - |
| 2021 | -1.5 | -0.02 | 0.98 | 0.00 | - |
| 2022 | -0.7 | 0.03 | 0.56 | 0.00 | - |
| 2023 | -1.5 | 0.06 | 1.06 | 0.00 | - |
| 2024 | -1.7 | 0.05 | 1.41 | 0.00 | - |
| 2025 | 6.2 | -0.05 | 1.23 | 1.97 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2017 | $-0.64 | $0.00 | $-4.6M | - |
| 2018 | $-0.64 | $0.00 | $-8.93M | - |
| 2019 | $-1.15 | $0.00 | $-41.14M | - |
| 2020 | $-1.99 | $0.00 | $-65.48M | - |
| 2021 | $-3.40 | $0.00 | $-123.2M | - |
| 2022 | $-2.33 | $0.00 | $-84.52M | - |
| 2023 | $-1.88 | $0.00 | $-82.44M | - |
| 2024 | $-1.27 | $0.00 | $-69.68M | - |
| 2025 | $0.39 | $70M | $22.37M | 32% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.64 | $-0.85 – $-0.28 | $7.14M | $7.14M – $7.14M | 7 |
| 2027 | $-1.01 | $-2.15 – $-0.49 | $2.85M | $2.85M – $2.85M | 6 |
| 2028 | $-0.91 | $-1.72 – $-0.51 | $11.59M | $11.59M – $11.59M | 7 |
| 2029 | $-1.22 | $-1.22 – $-1.22 | $13.34M | $13.34M – $13.34M | 2 |
| 2030 | $-0.81 | $-0.81 – $-0.81 | $73.24M | $73.24M – $73.24M | 5 |
